The FDA approved Relyvrio, a drug developed by Amylyx Pharmaceuticals, after extensive discussions about the safety and efficacy of the drug. Used to treat adults with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, the drug was initially rejected by an FDA advisory panel in March of this year. Earlier this month, the panel reconvened and reanalyzed, voting in favor of Relyvrio after being presented with additional data. The final ruling was delivered on September 29, 2022.

“FDA approval of Relyvrio is an exciting milestone for the ALS community and is a major step toward achieving our mission to one day end the suffering caused by neurodegenerative diseases,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx.